Sector: Healthcare | Industry: Pharmaceuticals |
Company Contact | |
Address: | 3009 Boul. De La Concorde East, Suite 102 LAVAL QC H7E 2B5 |
Tel: | 1-617-3084306 |
Website: | https://www.acasti.com/en |
IR: | See website |
Key People | ||
Roderick Noel Carter Independent Chairman of the Board | Prashant Kohli Chief Executive Officer | Robert J. Delaversano Principal Financial Officer, Principal Accounting Officer |
Carrie D'Andrea Vice President - Clinical Operations | Amresh Kumar Vice President - Program Management | R. Loch Macdonald Chief Medical Officer |
Business Overview |
Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company's clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection. |
Financial Overview |
For the nine months ended 31 December 2023, Acasti Pharma Inc revenues was not reported. Net loss decreased 27% to $9.7M. Lower net loss reflects Research and development expenses - Bala decrease of 82% to $1.1M (expense), Salaries and benefits decrease of 46% to $807K (expense), Interest income increase from $64K to $662K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$1.80 to -$1.18. |
Employees: | 32 as of Mar 31, 2021 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $7.08M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$12.21M as of Dec 31, 2023 |
Net annual income (TTM): | -$38.77M as of Dec 31, 2023 |
Free cash flow (TTM): | -$13.58M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 9,399,404 as of Dec 31, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |